Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/117328
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, James P.-
dc.contributor.authorHurst, Jacob-
dc.contributor.authorStöhr, Wolfgang-
dc.contributor.authorRobinson, Nicola-
dc.contributor.authorBrown, Helen-
dc.contributor.authorFisher, Martin-
dc.contributor.authorKinloch, Sabine-
dc.contributor.authorCooper, David A.-
dc.contributor.authorSchechter, Mauro-
dc.contributor.authorTambussi, Giuseppe-
dc.contributor.authorFidler, Sarah-
dc.contributor.authorCarrington, Mary-
dc.contributor.authorBabiker, Abdel-
dc.contributor.authorWeber, Jonathan-
dc.contributor.authorKoelsch, Kersten K.-
dc.contributor.authorKelleher, Anthony D.-
dc.contributor.authorPhillips, Rodney E.-
dc.contributor.authorFrater, John-
dc.contributor.authorMiró Meda, José M.-
dc.contributor.authorGatell, José M.-
dc.contributor.authorSPARTAC Trial Investigators-
dc.date.accessioned2017-11-02T12:27:38Z-
dc.date.available2017-11-02T12:27:38Z-
dc.date.issued2014-09-12-
dc.identifier.issn2050-084X-
dc.identifier.urihttp://hdl.handle.net/2445/117328-
dc.description.abstractIn HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.-
dc.format.extent16 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publishereLife Sciences-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.7554/eLife.03821-
dc.relation.ispartofeLife, 2014, vol. 3, p. e03821-
dc.relation.urihttps://doi.org/10.7554/eLife.03821-
dc.rightscc-by (c) Williams, James P. et al., 2014-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationVIH (Virus)-
dc.subject.classificationAntiretrovirals-
dc.subject.classificationMalalties infeccioses-
dc.subject.classificationAssaigs clínics-
dc.subject.otherHIV (Viruses)-
dc.subject.otherAntiretroviral agents-
dc.subject.otherCommunicable diseases-
dc.subject.otherClinical trials-
dc.titleHIV-1 DNA predicts disease progression and post-treatment virological control-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec649160-
dc.date.updated2017-11-02T12:27:38Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid25217531-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
649160.pdf1.21 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons